Skip to main content
. 2020 Jun;8(11):685. doi: 10.21037/atm-20-2741

Figure 2.

Figure 2

Validation of adjusted MET copy number with the concurrence of driver mutations. Tissue (A,B,C) and plasma (D,E,F) samples were both used to validate the relationship of either non-adjusted (A,D) or adjusted (B,C,E,F) MET copy numbers with concurrent alterations in other oncogenic genes. (A,B,C) Tissue samples were collected from a total of 127 patients, including 53 patients with concurrent driver mutations and 74 with only MET as sole driver. (D,F) Plasma samples were collected from a total of 61 patients, including 29 patients with concurrent driver mutations and 32 with only MET as sole driver. (A,B,D,E) X-axis denotes the presence or absence of concurrent driver mutations. Y-axis denotes the MET copy numbers. (C,F) X-axis refers to the percentage of patients. Y-axis denotes the presence or absence of concurrent driver mutations. Black bar denotes low-level MET copy number patients (MET adCN ≤4.8). Gray bar denotes high-level MET copy number patients (MET adCN >4.8). MET, mesenchymal-epithelial transition factor; adCN, adjusted copy number.